NCT04077723
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 83 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 18 words
- Primary and study completion moved earlier from Mar 31, 2027 to Dec 28, 2026
- Secondary endpoints: details revised at 3 of 24 entries
- Site details revised at 1 of 35 sites
- Minor Trial sites reduced: 44 → 35 locationsv81
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 43 to 44
- Minor Study sites: 41 to 43v78
- Minor Study sites: 40 to 41v77
Show 29 earlier versionsHide 29 earlier versions
- Minor Study sites: 39 to 40v76
- Minor Study sites: 38 to 39v74
- Minor Study sites: 37 to 38v73
- Minor Site details revised at 1 of 37 sitesv71
- Minor Study sites: 35 to 37v68
- Minor Study sites: 33 to 35v67
- Notable Eligibility criteria shortened, about 6 words
- Study sites: 17 to 33
- Notable Phase: Phase 1 to Phase 1/2
- Primary and study completion dates: Mar 31, 2025 to Mar 31, 2027
- Eligibility criteria expanded, about 31 words
- Interventions: Glofitamab (Drug), Obinutuzumab (Drug), RO7227166 (Drug), Tocilizumab (Drug) to Englumafusp alfa (Drug), Glofitamab (Drug), Obinutuzumab (Drug), Tocilizumab (Drug)
- Minor Site details revised at 2 of 17 sitesv57
- Minor Site details revised at 1 of 17 sitesv55
- Minor Site details revised at 3 of 17 sitesv54
- Minor Site details revised at 5 of 17 sitesv53
- Minor Site details revised at 1 of 17 sitesv52
- Minor Site details revised at 2 of 17 sitesv51
- Minor Enrollment target: 420 to 498
- Site details revised at 3 of 17 sites
- Minor Study sites: 16 to 17v49
- Minor Site details revised at 1 of 16 sitesv48
- Minor Study sites: 15 to 16v47
- Minor Site details revised at 3 of 15 sitesv46
- Minor Site details revised at 4 of 15 sitesv45
- Notable Primary and study completion dates: Jan 5, 2023 to Mar 31, 2025
- Site details revised at 2 of 15 sites
- Minor Study sites: 14 to 15v43
- Minor Site details revised at 1 of 14 sitesv42
- Minor Study sites: 13 to 14v40
- Minor Study sites: 12 to 13v39
- Minor Site details revised at 1 of 12 sitesv38
- Minor Enrollment target: 362 to 420
- Site details revised at 1 of 12 sites
- Minor Site details revised at 2 of 12 sitesv36
- Study Status, Contacts/Locationsv34
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (24)
Show 19 moreShow less
Arms and interventions
Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab up to seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of englumafusp alfa. Englumafusp alfa will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
Dose-Expansion Stage: Participants with r/r diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), high-grade B-cell lymphoma (HGBCL), primary mediastinal B-cell lymphoma (PMBCL), and DLBCL arising from FL (transformed FL) will receive englumafusp alfa administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
Drugs: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab
Sites
35 sites in 12 countries
China 4, France 4, Italy 4, South Korea 4, United States 4, Denmark 3, Spain 3, Australia 2, Canada 2, New Zealand 2, United Kingdom 2, Belgium 1